Affiliation:
1. Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and
Technology, Kattankulathur, India
Abstract
Cancer is an abnormal or unusual growth of cells in the body with invasive
and migrating potential. It leads to loss of function, weakens the immune system, and is
the second leading cause of death worldwide. This makes it important to eliminate the
disease. Genetic predisposition imposes a high relative risk for several kinds of cancer.
Inherited genetic mutations are responsible for causing 5 to 10 percent of all cancers.
Scientists have investigated mutations in specific genes with more than 50 hereditary
cancer syndromes. For this, chromosome 18 was explored for its genes associated with
cancer and this study unveiled 30 genes involved in causing cancer. Of these, the genes
DCC, EPB41L3, MBD1 PHLPP1, and RBBP8 were the potential tumor suppressors.
This chromosome consists of the target genes of the transforming growth factor-beta
(TGF-β) signaling pathway. The SMAD family genes (SMAD4, SMAD7, and SMAD2)
are encoded by this chromosome, of which SMAD4 acts as a tumor suppressor.
SERPINB5 and TCF-4 were the potential oncogenes. The enzyme coded by TYMS was
a potential therapeutic target for chemotherapy. Several fusion genes of this
chromosome (SS18-SSX2B, SS18-SSX2, and SS18-SSX4) have been identified to cause
cancer. Therefore, this chapter provides a summary of the genes in chromosome 18 that
are involved in the initiation and proliferation of cancer and provides an insight into the
potential biomarkers and therapeutic targets for clinical application to develop a
cancer-free world.
Publisher
BENTHAM SCIENCE PUBLISHERS
Reference112 articles.
1. Kim H.W.; Lee J.; Paik K.; Kang J.; Kim J.; Hwang J.H.; Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern. Medicine (Baltimore) 2017,96(5),e5926
2. Dima S.O.; Tanase C.; Albulescu R.; Herlea V.; Chivu-Economescu M.; Purnichescu-Purtan R.; Dumitrascu T.; Duda D.G.; Popescu I.; An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. Pancreas 2012,41(7),1001-1007
3. Culig Z.; Proinflammatory cytokine interleukin-6 in prostate carcinogenesis. Am J Clin Exp Urol 2014,2(3),231-238
4. Nagakawa O.; Junicho A.; Akashi T.; Koizumi K.; Matsuda T.; Fuse H.; Saiki I.; Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells. Oncol Rep 2005,13(6),1217-1221
5. Jung S.; Yi L.; Jeong D.; Kim J.; An S.; Oh T.J.; Kim C.H.; Kim C.J.; Yang Y.; Kim K.I.; Lim J.S.; Lee M.S.; The role of ADCYAP1, adenylate cyclase activating polypeptide 1, as a methylation biomarker for the early detection of cervical cancer. Oncol Rep 2011,25(1),245-252